Antiproteinuric efficacy of losartan in comparison with amplodipine in non-diabetic proteinuric renal diseases: A double-blind, randomized clinical trial

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1806-1813

  Praga, Manuel ^a   Fernández Andrade, Carlos ^b   Luño, José ^c   Arias, Manuel ^d   Poveda, Rafael ^e   Mora, Jose ^f   Valles Prat, Marti ^g   Rivera, Francisco ^h   Galceran, Jose María ⁱ   Martínez Ara, Jorge ^j   Aguirre, Román ^k   Bernis, Carmen ^l   Marín, Rafael ^m   Campistol, Jose María ⁿ  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f FUNDACIÓ PUIGVERT   (Spain)

^g HOSPITAL JOSEP TRUETA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ Hospital de Palamos   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL DE GALDAKAO   (Spain)

^l HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^m HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁿ HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Angiotensin II blockade; Losartan; Progression of renal disease; Proteinuria; Transforming growth factor (TGF )

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENDOTHELIN; GROWTH FACTOR; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; POTASSIUM; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANEMIA; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FIBROGENESIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY TUBULE CELL; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION; VERTIGO;

ADULT; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY DISEASES; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RECEPTORS, ANGIOTENSIN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 10744231452     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg284     Document Type: Article

References (20)

1. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 1995; 123: 754-762
2. Locatelli F, Marcelli D, Comelli M et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure: Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996; 11: 461-467
3. Ruggenenti P, Perna A, Mosconi L et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998; 53: 1209-1216
4. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-597
5. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15
6. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508
7. Border WA, Noble NA. Transforming growth factor-β in kidney fibrosis: a target for gene therapy. Kidney Int 1997; 51: 1388-1396
8. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945
9. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863
10. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
11. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
12. Campistol JM, Iñigo P, Jiménez W et al. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-719
13. Nielsen S, Dollerup J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 month study. Nephrol Dial Transplant 1997; 12 [Suppl 2): 19-23
14. Chan JCN, Critchley JA, Tomlinson B et al. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80
15. Fernández Andrade C, Russo D, Iversen B et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998; 54 [Suppl 68]: S120-S124
16. Holdaas H, Hartmann A, Berg KJ et al. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998; 13: 3096-3102
17. Plum J, Bünten B, Németh R, Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223-2234
18. Laverman G, Henning RH, de Jong PE et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38: 1381-1384
19. Honkanen E, Teppo AM, Tornroth T et al. Urinary transforming growth factor-β1 in membranous glomerulonephritis. Nephrol Dial Transplant 1997; 12: 2562-2568
20. Morath C, Dechow C, Lehrke I et al. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 2001; 12: 2300-2309